Ind swift laboratories has received a disclosure from HCP Investments regarding the disposal of a significant stake in the pharmaceutical company. The Mauritius-based investor sold 6,503,423 equity shares, representing 7.5% of the total paid-up share capital, through open market transactions.

Transaction Details

The share disposal was executed over a period of five days, with specific timing and volume details outlined in the regulatory filing:

Shareholding Changes

The disposal has significantly altered HCP Investments' position in Ind-Swift Laboratories, with the investor's stake reducing substantially:

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. HCP Investments submitted the required documentation on April 21, 2026, which was subsequently forwarded by Ind-Swift Laboratories to both stock exchanges on April 22, 2026.

The company's total equity share capital stands at 86,711,558 shares, and HCP Investments confirmed it does not belong to the promoter or promoter group category. The transaction was signed off by Mr. Neermalsingh Poonie on behalf of HCP Investments from Mauritius.

Company Information

Ind-Swift Laboratories Limited operates manufacturing facilities in Punjab and Jammu & Kashmir, with its registered office located in Chandigarh. The company maintains Unit I at NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab, and Unit II at Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir.

Ind Swift Laboratories has provided clarification to BSE Limited regarding a sudden surge in trading volume, attributing the market activity to its recent arbitration award disclosure. The pharmaceutical company successfully concluded arbitration proceedings with PI Industries Limited, with the Arbitral Tribunal rejecting all claims from both parties.

BSE Surveillance Response

The company responded to BSE's inquiry dated April 9, 2026, regarding the unusual spike in share trading volume. Ind-Swift Laboratories confirmed that it has consistently disclosed all material information affecting company operations and performance in accordance with regulatory requirements.

The company stated it is not aware of any specific reason for the sudden volume surge except for the arbitration award disclosure made on April 7, 2026. Management emphasized that the trading activity appears purely market-driven and may result from various factors including prevailing market conditions.

Arbitration Award Details

The Arbitral Tribunal constituted by Mumbai Centre for International Arbitration (MCIA) delivered its final order on April 7, 2026. The tribunal comprehensively rejected all claims filed by PI Industries Limited as the claimant, while simultaneously dismissing all counterclaims submitted by Ind Swift Laboratories Limited and other respondents.

Regulatory Compliance

Ind-Swift Laboratories fulfilled its disclosure obligations under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company provided comprehensive details about the arbitration conclusion to both BSE Limited and National Stock Exchange of India Limited within stipulated timeframes.

The company reiterated its commitment to maintaining full compliance with SEBI Listing Regulations, 2015, and other applicable laws. All material information bearing on company operations and performance continues to be disclosed within required timelines.

Company Operations

Ind-Swift Laboratories Limited operates as a pharmaceutical company with its registered office in Chandigarh. The company maintains manufacturing facilities across two strategic locations - Unit I in Punjab and Unit II in Jammu & Kashmir. The successful arbitration conclusion removes any potential financial liability or uncertainty associated with the dispute, allowing focused attention on core pharmaceutical operations without pending legal proceedings overhang.